Clinical trials
Drug Resistance clinical trials
Below are recruiting drug resistance clinical trials, each written for real people, not researchers. We’re tracking 118 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06210022Recruiting
Cognitive problems in drug-resistant vs drug-responsive epilepsy
This study compares thinking skills in people with focal epilepsy that responds well to medication versus epilepsy that doesn't. It aims to understand how different types of epilepsy affect memory, attention, and other cognitive functions.
MilanAges 18–60 - NCT07486024RecruitingPhase 3
A new 6-month treatment for multidrug-resistant tuberculosis
This trial tests a new 6-month treatment for people with multidrug-resistant tuberculosis (MDR-TB). It aims to see if this shorter treatment works well and can be used in France, offering a quicker option for recovery.
AmiensAges 18 years+ - NCT07035535Enrolling by invitation
Using genetic tests to predict antibiotic resistance in lung infections
This trial looks at whether a special genetic test (tNGS) can predict which antibiotics will work for bacteria causing lung infections. It may help doctors choose the right treatment faster.
Nanjing, JiangsuAges 18 years+ - NCT07010445Recruiting
Gut-brain connection in resistant epilepsy
This study looks at how the gut and brain talk to each other in people with epilepsy, especially when seizures are hard to control. It may help find new ways to treat epilepsy by focusing on the gut.
Milan, LombardyAges 3–50 - NCT05835206RecruitingPhase 2
Drug to reduce antibiotic-resistant gut bacteria
This Phase 2 study tests whether an investigational treatment can help clear or reduce antibiotic-resistant bacteria living in the gut. It may help prevent these germs from causing future infections by targeting specific resistant bacteria found on stool or rectal swabs.
Atlanta, GeorgiaAges 18 years+ - NCT01212003Recruiting
Study of how tuberculosis develops over time
This study follows people with suspected or confirmed tuberculosis (TB), whether they have inactive “latent” TB or active TB. It helps researchers better understand TB’s natural course and may improve future testing and care by allowing collection and storage of samples.
Bethesda, MarylandAges 2–100 - NCT06321536RecruitingPhase 2
Testing microbiota therapy for resistant bacteria in the gut
This study tests a treatment made from healthy donor stool (called microbiota therapy) given as an enema or through a feeding tube. It aims to help people who carry resistant bacteria that are hard to treat, by reducing or clearing those bacteria from the gut.
Atlanta, GeorgiaAges 18 years+ - NCT07183748RecruitingPhase 2
Psilocybin microdosing plus therapy for hard-to-treat depression
This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.
BeershebaAges 18–65 - NCT06843668RecruitingPhase 2/Phase 3
Best ways to give colistin for tough infections in the ICU
This study tests different ways of giving the antibiotic colistin to patients in the ICU with infections that are hard to treat. The goal is to find the best dosing schedule to help you fight the infection more effectively.
BuraidahAges 18 years+ - NCT04098315Recruiting
HIV drug-resistance patient registry study for people 14+
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
Milan, MIAges 14 years+ - NCT07073755Recruiting
Study of next treatments after targeted therapy resistance for advanced breast cancer
This study looks at what happens when people with advanced breast cancer switch to a new treatment after their cancer becomes resistant to targeted therapies like CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd. Researchers want to understand which next treatments work best in real life.
Changsha, HunanAges 18 years+ - NCT07071103RecruitingPhase 2
Low-dose radiation and immunotherapy for resistant solid tumors
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
Shantou, GuangdongAges 18–80 - NCT07434986Recruiting
Overnight brain stimulation for temporal lobe epilepsy
This study tests whether a gentle magnetic device applied overnight can help reduce seizures in people with temporal lobe epilepsy. You'll stay in a sleep lab for one night while we monitor your brain waves and sleep.
Durham, North CarolinaAges 18–70 - NCT07546253Recruiting
Tracking outcomes for brain ablation in drug-resistant epilepsy
This trial is a registry that tracks real-world outcomes for people with drug-resistant epilepsy who are treated with the NeuroOne OneRF ablation system. Participants receive a standard procedure (RF ablation) and their health data is collected to help improve future care.
Miami, FloridaAges Any age - NCT05459090Recruiting
Study of how brain “brakes” work in drug-resistant temporal epilepsy
This study looks at how the brain’s natural “braking” system works in people with drug-resistant temporal lobe epilepsy. It may help researchers better understand the condition in order to improve future treatments.
Pozzilli, IserniaAges Any age - NCT05534672RecruitingPhase 3
Rapamycin for drug-resistant seizures in tuberous sclerosis
This trial tests whether rapamycin (compared with a placebo) can reduce seizures caused by tuberous sclerosis complex (TSC) that have not been controlled by usual medicines. If you qualify, you may be helping doctors find a safer and more effective option for seizure control.
LodzAges 3 months–50 years - NCT05983276RecruitingPhase 2
Combination therapy for drug-resistant ovarian cancer
This trial tests a new two-drug combination (decitabine and selinexor) given with standard chemotherapy to see if it can reverse drug resistance in ovarian cancer that has come back or worsened after treatment.
Maywood, IllinoisAges 18 years+ - NCT06353620Recruiting
Brain connections study for certain epilepsies and genetic syndromes
This study uses MRI and a special EEG to understand brain connections in people with specific types of epilepsy or genetic conditions like Angelman syndrome and Dup15q. It may help find better ways to treat these conditions.
Conegliano, TrevisoAges 6–75 - NCT05609084Recruiting
Speech therapy before surgery for drug-resistant temporal epilepsy
This study tests an intensive pre-surgery speech rehabilitation program for people whose seizures come from the language-related area in the temporal part of the brain. The goal is to improve speech outcomes before planned epilepsy surgery.
BordeauxAges 16 years+ - NCT07716930Enrolling by invitation
Eye scan study for drug-resistant epilepsy
This study uses a special eye scan (OCT) to look for changes in the retina that might be linked to hard-to-control epilepsy. The goal is to find new biomarkers that could help doctors better understand and manage the condition.
IstanbulAges 18–40 - NCT07605858Recruiting
Epilepsy, Sleep, and Brain Activity Study
This study examines how seizures affect sleep quality and dreams in people with hard-to-treat focal epilepsy. Researchers will use specialized brain electrodes to understand these connections during sleep, which may help improve treatment in the future.
Durham, North CarolinaAges 18–55 - NCT06641778Recruiting
Fecal transplant for drug-resistant Klebsiella pneumonia
This trial tests whether transplanting healthy donor stool into the lungs can help treat a severe pneumonia caused by a bacteria that is resistant to many antibiotics. It may offer a new option for people whose infection is not responding to standard treatments.
Wuhan, HubeiAges 18–75 - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT06719791RecruitingEarly Phase 1
Sirolimus for hard-to-treat focal epilepsy
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
BeijingAges 18–60
Hear when a new Drug Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for drug resistance?
- Yes. Clin2 currently lists 118 recruiting drug resistance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a drug resistance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a drug resistance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.